Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
Globe Newswire•24/07/2026•07:30 ET
0
Whiz Insights
Get started
Create a free account to read the full story.